Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald S Bloomfield

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialPamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances|January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trialRomit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
JACC. Advances|May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T Lu, Heather J Ribaudo, Sara McCallum, et al.
The Journal of Clinical Investigation|September 9, 2025
Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIVMárton Kolossváry, Irini Sereti, Markella V Zanni, et al.
JACC. Advances|September 10, 2024
Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIVChristopher deFilippi, Sara McCallum, Markella V Zanni, et al.
AIDS (London, England)|December 16, 2022
Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIVPamela S Douglas, Sara McCallum, Michael T Lu, et al.
Open Forum Infectious Diseases|April 10, 2025
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial CohortEmma Davies Smith, Carlos Malvestutto, Heather J Ribaudo, et al.
The Lancet. HIV|May 1, 2026
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trialEsteban Martínez, Maya Watanabe, Risa Hoffman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2023
Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE CohortBorek Foldyna, Thomas Mayrhofer, Markella V Zanni, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialPamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances|January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trialRomit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
JACC. Advances|May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T Lu, Heather J Ribaudo, Sara McCallum, et al.
The Journal of Clinical Investigation|September 9, 2025
Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIVMárton Kolossváry, Irini Sereti, Markella V Zanni, et al.
JACC. Advances|September 10, 2024
Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIVChristopher deFilippi, Sara McCallum, Markella V Zanni, et al.
AIDS (London, England)|December 16, 2022
Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIVPamela S Douglas, Sara McCallum, Michael T Lu, et al.
Open Forum Infectious Diseases|April 10, 2025
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial CohortEmma Davies Smith, Carlos Malvestutto, Heather J Ribaudo, et al.
The Lancet. HIV|May 1, 2026
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trialEsteban Martínez, Maya Watanabe, Risa Hoffman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 13, 2023
Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE CohortBorek Foldyna, Thomas Mayrhofer, Markella V Zanni, et al.
Pageof 19